Patents Examined by Carlos A. Azpuru
  • Patent number: 11911352
    Abstract: A method of forming an implant in tissue can include: providing a polymer solution having an effective amount of polymer dissolved in a biocompatible, water-soluble organic solvent; injecting a plurality of droplets of the polymer solution in the tissue; fusing the injected droplets together; dissipating the biocompatible, water-soluble organic solvent in the tissue; and precipitating the polymer from the injected polymer solution so as to form the implant.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: February 27, 2024
    Assignee: PATHAK HOLDINGS LLC
    Inventor: Chandrashekhar P. Pathak
  • Patent number: 11911400
    Abstract: Two vial containing kits containing aspirin for intravenous administration are disclosed. The first vial contains a lyophilized mixture of aspirin in crystalline form, a bulking agent such as mannitol and a surfactant. The second vial includes an aqueous diluent such as water for injection and a basifying agent such as Tris.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: February 27, 2024
    Assignee: RHOSHAN PHARMACEUTICALS, INC.
    Inventor: Nagesh R. Palepu
  • Patent number: 11911350
    Abstract: A reduced coenzyme Q10-containing composition has high water solubility and excellent storage stability. A powder composition contains the reduced coenzyme Q10, starch octenylsuccinate, and gum Arabic. A method of producing the powder composition includes homogenizing the ingredients in water to obtain an emulsion composition; and drying the composition.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 27, 2024
    Assignee: Petroeuroasia Co., Ltd.
    Inventor: Hidehiro Takahashi
  • Patent number: 11910795
    Abstract: This disclosure features herbicidal compositions including one or more indole auxins and methods of making and using the same.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: February 27, 2024
    Assignee: Suncor Energy Inc.
    Inventors: Jun Liu, Michael Fefer
  • Patent number: 11911385
    Abstract: The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: February 27, 2024
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Stephen Gitu Machatha, Dean Eliott, Tomasz Stryjewski
  • Patent number: 11911476
    Abstract: The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 27, 2024
    Assignee: PK MED
    Inventors: Philippe Pouletty, Frédérique Guillamot
  • Patent number: 11911508
    Abstract: The present invention relates to: sustained-release microparticles capable of maintaining, for a long time, effects of preventing, treating or alleviating benign prostatic hyperplasia and prostate cancer and effects of preventing hair loss and promoting hair growth according to the administration of microparticles containing dutasteride; and a preparation method therefor, and according to the use of a method for administering the particles to a patient through an injection, a patient does not have to directly store or handle the microparticles, unlike an oral dosage form, and thus storage and handling are simple. In addition, drug effects are maintained for a long period of time of 1-3 months and, simultaneously, administration through injection can be facilitated since foreign body sensation and pain are reduced when being administered to a patient through injection because of the constant average diameter of the particles.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: February 27, 2024
    Assignee: INVENTAGE LAB INC.
    Inventors: Ju Hee Kim, Se Yeon Kim
  • Patent number: 11903387
    Abstract: The present invention relates to a method of controlling plant diseases caused by phytopathogenic microorganisms, comprising a step of applying a fungicidal composition comprising a compound of formula [1] or a salt thereof.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: February 20, 2024
    Assignee: Gowan Company, L.L.C.
    Inventors: Takatoshi Sakaguchi, Naoki Okada
  • Patent number: 11903976
    Abstract: Disclosed are an implantable therapeutic delivery system and methods of treatment utilizing the implantable therapeutic delivery system. The implantable therapeutic delivery system includes a nanofibrous core substrate including one or more internal spaces wherein one or more therapeutic agents is positioned in the one or more internal spaces; and an outer biocompatible polymeric coating surrounding said nanofibrous core substrate.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: February 20, 2024
    Assignee: CORNELL UNIVERSITY
    Inventors: Minglin Ma, James A. Flanders, Duo An
  • Patent number: 11905377
    Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 20, 2024
    Assignees: Pendant Biosciences, Inc., The Governing Council of the University of Toronto
    Inventors: Timothy Tordella Ruckh, Carl Eric Elmquist, David Michael Stevens, Frantz Le Dévédec, Hilary Boucher, Christine Allen
  • Patent number: 11896677
    Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: February 13, 2024
    Assignee: HDT Bio Corp.
    Inventors: Amit Khandhar, Steven Reed, Malcolm Duthie, Jesse Erasmus, Darrick Carter, Bryan J. Berube
  • Patent number: 11890393
    Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: February 6, 2024
    Assignees: Tulavi Therapeutics, Inc., Incept, LLC
    Inventors: Corinne Bright, Yong Ren, Kenneth M. Martin, Farhad Khosravi, Amarpreet S. Sawhney
  • Patent number: 11883542
    Abstract: A chitosan film including ternary metal oxides. In an embodiment, the ternary metal oxides can include tungsten oxide nanoparticles (WO3 NPs), magnesium oxide nanoparticles (MgO NPs), and a graphene oxide (GO) layer. In an embodiment the chitosan film is porous. The chitosan film including ternary metal oxides can be used as a wound dressing for the clinical management of bacterially infected wounds.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: January 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda, Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed
  • Patent number: 11883525
    Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: January 30, 2024
    Assignee: DOSE MEDICAL CORPORATION
    Inventors: Patrick Michael Hughes, James Shiah, Jack Xie, Jia-Ying Yang
  • Patent number: 11878087
    Abstract: Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: January 23, 2024
    Assignee: Tepha, Inc.
    Inventors: Simon F. Williams, Said Rizk, David P. Martin
  • Patent number: 11878076
    Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: January 23, 2024
    Assignee: NIVAGEN PHARMACEUTICALS, INC.
    Inventors: Bala Tripura Sundari Chodavarapu, Thirupathi Mangali, Jay Shukla, Anand Shukla, Dasaradhi Lakkaraju
  • Patent number: 11878092
    Abstract: In accordance with some aspects, the present disclosure is directed to medical compositions that comprises (a) a first hydrophilic polymer functionalized with a plurality of first functional groups and (b) a second hydrophilic polymer functionalized with a plurality of second functional groups, wherein the first and second functional groups are selected to react and form covalent bonds upon a change in conditions such that the first and second hydrophilic polymers crosslink with one another. In other aspects the present disclosure is directed to kits that comprise such medical compositions and to medical procedures that utilize such medical compositions.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: January 23, 2024
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Lauren Lydecker, Jennifer Whelehan
  • Patent number: 11878028
    Abstract: The present invention discloses a pharmaceutical composition comprising azvudine and an EGFR/TKI inhibitor. The pharmaceutical composition of the present invention shows a good synergistic effect in antitumor, and can delay the generation of drug resistance and improve the therapeutic effect and safety, thereby achieving the goal of prolonging the survival of patients.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: January 23, 2024
    Assignee: HENAN GENUINE BIOTECH CO., LTD.
    Inventors: Pan Li, Limin Jia, Zhiyong Qin, Zhaoyang Wang
  • Patent number: 11878043
    Abstract: Amaranthus hybridus silver nanoparticles can be synthesized by mixing an extract of Amaranthus hybridus with a silver nitrate solution to provide a mixture including Amaranthus hybridus silver nanoparticles. The Amaranthus hybridus silver nanoparticles can have an average particle size ranging from about 45 nm to about 100 nm. The AH-AgNPs can have antifungal properties and can be particularly effective agents against Madurella mycetomatis, for the treatment of eumycetoma.
    Type: Grant
    Filed: June 12, 2023
    Date of Patent: January 23, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Enas Mohamed Ali, Basem Mohamed Abdallah Abdelsalam
  • Patent number: 11872293
    Abstract: Embodiments described herein are related to pellets that are placed within an extraction site that is in need of bone augmentation and preservation. The pellets are typically cylindrical in shape and comprise a material and a polymer coating. The pellets may advantageously facilitate sufficient new bone growth that jaw bone deterioration is prevented. The pellets create, arrange, and assemble an ideal growth environment for new bone growth to rapidly grow and preserve the original contours of an individual's jaw bone.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: January 16, 2024
    Assignee: INNOVATIVE HEALTH TECHNOLOGIES, LLC
    Inventor: Darnell Kaigler, Sr.